305 related articles for article (PubMed ID: 29415975)
1. Detection of Minimal Bone Marrow involvement of Blastic Plasmacytoid Dendritic Cell Neoplastic Cells - CD303 immunostaining as a diagnostic tool.
Ohe R; Aung NY; Shiono Y; Utsunomiya A; Kabasawa T; Tamazawa N; Tamura Y; Kato T; Yamada A; Hasegawa S; Aizawa K; Inokura K; Ito S; Toubai T; Kato Y; Tsunoda T; Onami K; Suzuki T; Ishizawa K; Yamakawa M
J Clin Exp Hematop; 2018 Mar; 58(1):1-9. PubMed ID: 29415975
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of 46 cases with CD4
Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
[TBL] [Abstract][Full Text] [Related]
4. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
Cheng W; Yu TT; Tang AP; He Young K; Yu L
Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.
Wang W; Khoury JD; Miranda RN; Jorgensen JL; Xu J; Loghavi S; Li S; Pemmaraju N; Nguyen T; Medeiros LJ; Wang SA
Haematologica; 2021 Apr; 106(4):1047-1055. PubMed ID: 32241840
[TBL] [Abstract][Full Text] [Related]
6. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
Wilson NR; Bover L; Konopleva M; Han L; Neelapu S; Pemmaraju N
Leuk Lymphoma; 2022 Jan; 63(1):19-30. PubMed ID: 34486917
[TBL] [Abstract][Full Text] [Related]
7. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
Wu SJ; Sadigh S; Lane AA; Pinkus GS
Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
[TBL] [Abstract][Full Text] [Related]
8. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
9. Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset.
Yu H; Zhang P; Yin X; Yin Z; Shi Q; Cui Y; Liu G; Wang S; Piccaluga PP; Jiang T; Zhang L
Protein Cell; 2015 Apr; 6(4):297-306. PubMed ID: 25779340
[TBL] [Abstract][Full Text] [Related]
10. Blastic plasmacytoid dendritic cell neoplasm : report of two cases.
Tsunoda K; Satoh T; Akasaka K; Ishikawa Y; Ishida Y; Masuda T; Akasaka T
J Clin Exp Hematop; 2012; 52(1):23-9. PubMed ID: 22706527
[TBL] [Abstract][Full Text] [Related]
11. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm.
Sangle NA; Schmidt RL; Patel JL; Medeiros LJ; Agarwal AM; Perkins SL; Salama ME
Mod Pathol; 2014 Aug; 27(8):1137-43. PubMed ID: 24390220
[TBL] [Abstract][Full Text] [Related]
12. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract][Full Text] [Related]
13. Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis.
Deconinck E; Petrella T; Garnache Ottou F
Hematol Oncol Clin North Am; 2020 Jun; 34(3):491-500. PubMed ID: 32336414
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
15. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
16. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality.
Sumarriva Lezama L; Chisholm KM; Carneal E; Nagy A; Cascio MJ; Yan J; Chang CC; Cherry A; George TI; Ohgami RS
Histopathology; 2018 Nov; 73(5):767-776. PubMed ID: 29884995
[TBL] [Abstract][Full Text] [Related]
17. [Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face].
Ahogo KC; Wantz M; Cliquennois M; Gosset P; Lebas D; Modiano P
Ann Dermatol Venereol; 2014 Jan; 141(1):43-7. PubMed ID: 24461094
[TBL] [Abstract][Full Text] [Related]
18. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
19. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
Tang H; Panse G; Braddock D; Perincheri S; Xu ML; McNiff JM
J Cutan Pathol; 2023 Jul; 50(7):595-600. PubMed ID: 37082914
[TBL] [Abstract][Full Text] [Related]
20. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients.
Julia F; Dalle S; Duru G; Balme B; Vergier B; Ortonne N; Vignon-Pennamen MD; Costes-Martineau V; Lamant L; Dalac S; Delattre C; Déchelotte P; Courville P; Carlotti A; De Muret A; Fraitag S; Levy A; Mitchell A; Petrella T
Am J Surg Pathol; 2014 May; 38(5):673-80. PubMed ID: 24441662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
